MedTrace Logo

Cannabinoids, Learning, and Memory

NCT02407808 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-04-29

No results posted yet for this study

Summary

The overarching goal of this study is to characterize the effects of cannabinoids on working and episodic memory.

Conditions

  • Cannabis
  • Psychotic Disorders

Interventions

DRUG

THC

Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.

DRUG

Placebo

Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Mohini Ranganathan, M.D. · Assistant Professor

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2018-08-10
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02407808 on ClinicalTrials.gov